# Gastrointestinal–Renal Axis: Role in the Regulation of Blood Pressure

Jian Yang, MD, PhD; Pedro A. Jose, MD, PhD; Chunyu Zeng, MD, PhD

Hypertension is one of the most common and important health problems worldwide.[1] It has been estimated that 29% of the world's adult population, or 1.56 billion people, will have hypertension by the year 2025.[2] The prevalence of high blood pressure and its adverse consequences result in a heavy burden for hypertensive patients from high-, middle-, and low-income countries.[2,3] Many monogenic causes of hypertension have been reported. However, determining the causes of essential hypertension has been hampered because it is a complex disorder with genetic, epigenetic, and environmental determinants. Among numerous environmental factors, sodium intake is thought to be an important one.

Sodium is essential for cellular homeostasis and fluid balance. However, excessive sodium in the body, as a consequence of increased dietary intake and/or impaired excretion, is the most common risk factor for hypertension.[4] There is overwhelming evidence that high dietary sodium intake increases the risk for incident hypertension and leads to worse cardiovascular outcomes.[4,5] Excess sodium intake also attenuates the beneficial effects of many antihypertensive drugs, including blockers of the renin–angiotensin system (RAS).[6] A modest reduction in dietary salt intake causes a significant fall in blood pressure in both hypertensive and normotensive individuals.[7] Therefore, a low-sodium diet is a major preventive and treatment scheme for hypertension.[8]

The kidney plays a vital role in the regulation of sodium balance and blood pressure. However, the gastrointestinal (GI) tract, which is the organ first exposed to components of food, has taste receptors and sensors for electrolytes (eg,

sodium, potassium, phosphate).[9] Therefore, in addition to the kidney, there is increasing realization of the importance of the GI tract in the regulation of sodium balance, and consequently on blood pressure level. For example, GI tract–derived hormones and peptides regulate the autocrine function of renal hormones, affecting renal function, including sodium excretion.[10] We have reported that the GI tract–derived hormone, gastrin, and renal receptors synergistically regulate sodium excretion.[11] In this article, we present an overview of GI tract–mediated regulation of blood pressure, highlight potential strategies for the prevention and treatment of hypertension, and also attempt a look into the future.

## Renal Regulation of Sodium Homeostasis

The kidney is crucial in the long-term control of blood pressure by regulating sodium homeostasis.[12] This concept has been confirmed by renal transplantation studies in humans and experimental animals.[13–17] For example, transplantation of kidneys from adult stroke-prone spontaneously hypertensive rats (SPSHR) causes hypertension in normotensive Wistar-Kyoto (WKY) rats, indicating a major role of the kidney in SPSHR hypertension[18]; we have also reported that germline deletion of the $D_5$ dopamine receptor ($D_5R$) causes salt-sensitive hypertension. Blood pressure was similar between wild-type mice and wild-type mice transplanted with wild-type kidneys, while blood pressure was higher in wild-type mice transplanted with $D_5R^{-/-}$ kidneys than wild-type kidneys, which also indicates the importance of the kidney in the development of hypertension.[17] All nephron segments of the kidney, including the proximal tubule and medullary thick ascending limb of Henle, participate in the regulation of blood pressure.[19–23] The renal proximal tubule (RPT) is responsible for 65% to 70% of filtered sodium and water reabsorption under normal conditions. Indeed, several studies have shown that human essential hypertension is associated with increased sodium transport in the RPT.[21–23] The inappropriate sodium retention in hypertension results from an enhanced renal sodium transport per se, as well as a failure to respond appropriately to signals that decrease renal sodium transport in the face of increased sodium intake.

*From the Departments of Nutrition (J.Y.) and Cardiology (J.Y., C.Z.), Daping Hospital, The Third Military Medical University, Chongqing, China; Division of Renal Disease & Hypertension, The George Washington University School of Medicine and Health Sciences, Washington, DC (P.A.J.).*

**Correspondence to:** Chunyu Zeng, MD, PhD, Department of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, China. E-mail: chunyuzeng01@sina.com

Sodium reabsorption in the RPT is controlled through ion cotransporters/exchangers/pump,[19] such as the sodium glucose cotransporter, sodium amino acid cotransporter, sodium hydrogen exchanger (NHE), sodium phosphate cotransporter type 2, sodium bicarbonate cotransporter, and NBCe2, located at the luminal/apical membrane, and NBCe1 and $Na^+$-$K^+$-ATPase located at the basolateral membrane, among others.[19–25] These sodium cotransporters, exchangers, and pump are influenced by numerous neural, hormonal, and humoral factors. These neural, hormonal, and humoral factors can be divided into 2 groups based on their effects on sodium excretion. One group leads to natriuresis, while the other group leads to antinatriuresis (ie, decreased sodium excretion). These 2 groups keep the sodium balance and ultimately blood pressure within the normal range. Renal dopamine and angiotensin II (Ang II), via dopamine receptors or $AT_1$ receptor, are examples of members of these 2 opposing groups. Thus, in general, activation of renal dopamine receptors leads to diuresis and natriuresis, whereas activation of renal $AT_1$ receptors leads to antidiuresis and antinatriuresis. In several hypertensive states, dopamine receptor–induced natriuresis is decreased and $AT_1$ receptor-mediated antinatriuresis is augmented, which consequently lead to sodium retention and hypertension.[12,19–23,26,27]

## Salt Sensing and Absorption in the GI Tract

Salt sensing is a complex physiological response. The objective of salt sensing is to keep the sodium balance in the normal range. Indeed, salt sensing occurs in many organs of the body, including the GI tract, from the tongue, stomach, and small and large intestines.[28–33] As aforementioned, the GI tract is the first organ exposed to ingested sodium. In the salt-depleted state, sensing the need for sodium in the tongue and stomach would lead the person to ingest more salt,[34] and in the addition, make the GI tract secrete hormones that increase absorption/reabsorption of sodium in different organs in the body, including the kidney. The converse occurs in the salt-replete state; less salt is ingested and the GI tract triggers the mechanisms to induce natriuresis and diuresis. Sodium given orally is excreted more rapidly than that administered intravenously in many but not all studies.[9,10,35–38] The negative studies should not be taken to dispute the presence of a "gastro-renal reflex" because there are sodium sensors outside the GI tract and kidney (eg, vascular smooth muscles) that "instruct" the kidney to decrease sodium transport.[39] These mechanisms include the recruitment of aversive taste pathways by activating the sour- and bitter-taste–sensing cells, and taste receptors in the kidney.[40–42] Therefore, the targeting of sodium sensors in different parts of the body, including those in the GI tract, may represent new targets for antihypertensive therapy.

## Salt Sensing in the Oral Cavity Controls Salt Intake

The oral cavity is the first organ in the GI tract to be exposed to food and nutrients. The taste system is a chemical detection system in the oral cavity, where tastants act as cues for salty, sweet, umami, bitter, and sour tastes on taste buds; a sixth taste (lipid) has also been proposed.[43] A single taste bud contains 50 to 100 taste cells that detect sugars, amino acids, poisons, acids, and minerals. Taste receptors have been identified as ion channels (for salt or sour detection) or G-protein coupled receptors, which are responsive to bitter, sweet, or umami.[44] Interestingly, different from the other 4 tastes, salty taste is unique in that increasing salt concentration fundamentally transforms an innately appetitive stimulus into a powerfully aversive one. This appetitive–aversive balance helps to maintain appropriate salt consumption.[40]

Salt (sodium) can also be sensed by taste receptors, via amiloride-sensitive and -insensitive pathways. Low concentrations (attractive) of NaCl (<100 mmol/L) stimulate the attractive salt taste pathway that is selective for sodium and blocked by amiloride.[40,45,46] High concentration (aversive) of NaCl (>150 mmol/L) is nonselective for sodium and is amiloride insensitive.[45,47] Mice lacking ENaCα selectively in taste receptor cells exhibit a complete loss of salt attraction and sodium taste responses, without affecting taste for sour, bitter, sweet, and umami or the aversive salt pathway.[45] However, high salt in food also recruits the 2 primary aversive taste pathways, ie, sour and bitter, which may have evolved to ensure that high levels of salt reliably trigger robust behavioral rejection, thus preventing its potentially detrimental effect,[40] including hypertension. By contrast, the amiloride-insensitive mechanism, which predominates in circumvallate and foliate taste buds, is involved with a variant of the nonselective cation channel TRPV1 and other salt transduction mechanisms.[47]

The amiloride-sensitive salt taste response is regulated by hormones and humoral factors,[48,49] including Ang II, aldosterone, ghrelin, and insulin.[50,51] Ang II and aldosterone, which are stimulated in states of sodium deficit and are important in the maintenance of a positive sodium balance, also affect salt appetite. The $AT_1$ receptor and ENaC have been shown to colocalize in a subset of mouse taste bud cells.[50] Whether or not the mineralocorticoid receptor also colocalizes with ENaC in this subset of mouse taste buds has not been shown, but aldosterone has been reported to increase the expression of β and γENaC and ENaC activity in these cells.[51] Shigemura et al suggested that Ang II may increase sodium intake by reducing

amiloride-sensitive taste response that is subsequently suppressed by aldosterone via enhancement of the amiloride-sensitive taste response.[50]

The taste of salt may be altered in hypertension. Some hypertensive patients have higher salt taste sensitivity threshold than normotensives subjects.[52–54] A similar phenomenon may be found in some hypertensive animals. Thus, compared with WKY rats, SHRs have a greater preference for saline and this preference for saline is not related to the existing blood pressure.[55,56] However, Dahl-salt sensitive rats have lower salt intake than Dahl-salt resistant rats.[57] Salt sensitivity of blood pressure also does not correlate with salt appetite in mice.[58] Interestingly, taste sensitivity is decreased in smokers.[46] Impaired taste of salt has been reported to be associated with hypertension in Japanese women; there is a higher prevalence of hypertension in Japanese men married to Japanese women with impaired taste of salt.[59]

## GI Tract and Sodium Absorption

The GI tract is responsible for the digestion and absorption of ingested food and nutrients. Another essential function of the GI tract is the coordinated regulation of the secretion and absorption of electrolytes, minerals, and fluids. In healthy adult humans, the GI tract is filled with secreted fluid amounting to 8 to 10 L per day with an additional 1.5 to 2 L per day from ingested food. Most of the electrolytes and fluids are absorbed by the small ($\approx$95%) and large ($\approx$4%) intestines. The intestinal absorption of fluid by GI epithelial cells occurs via active transport of $Na^+$ and $Cl^-$[60,61]; NaCl absorption occurs from the small intestine to the distal colon. Healthy adult humans ingest about 250 to 300 mmol sodium per day. However, there is less than 4 mmol sodium in the excrement, suggesting that almost all of NaCl is absorbed in the GI tract. Apparently, there is no difference in sodium absorption between hypertensive patients and healthy controls and Dahl salt-sensitive and salt-resistant rats.[62] Thus, an augmented ability of the intestines to absorb sodium does not participate in the pathogenesis of most cases of hypertension. However, dietary fructose increases sodium absorption by the intestines.[63] Increased intestinal sodium absorption is associated with increased blood pressure in elderly humans.[64] However, NHE activity is increased in the jejunum and ileum of younger (6–9 weeks) but not older (12 weeks) spontaneously hypertensive rats.[65,66] NHE2, NHE3, and NHE8 are found at the brush border membrane of the small intestinal epithelium. Studies in $Nhe2^{-/-}$ and $Nhe3^{-/-}$ mice have demonstrated that NHE3 accounts for most of the neutral NaCl absorption in the small intestine.[60,67] Inhibition of NHE3 activity only in the GI tract decreased urinary sodium excretion and increased stool sodium by similar amounts but to a lesser degree

($\approx$20–50 mmol sodium/day) in humans than in rats.[61,68] Angiotensin-converting enzyme inhibition by ramipril plus intestinal NHE3 inhibition results in an additive blood pressure–lowering effect.[68] In the colon, sodium absorption is mediated by ENaC; a high salt diet decreases the expression of $\beta$ and $\gamma$ ENaC.[69] These suggest that intestinal NHE3 and ENaC blockade could be new treatment strategies for hypertension.

## Gut-Derived Hormones, Secreted in Response to Salt Sensors, Modulate Renal Sodium Excretion

The theories and findings underpinning the GI-mediated natriuretic signaling still remain partially solved or incomplete. Nevertheless it is now clear that GI-derived hormones and peptides play important roles in the regulation of renal sodium transport and blood pressure.[10] The GI-derived hormones could be grouped into 3 classes, namely, GI hormones, pancreatic hormones, and GI neuropeptides. According to their ability to affect sodium excretion, we classify these hormones and neuropeptides into 2 classes; 1 increases and the other decreases sodium excretion (Table).[70–101]

In the hypertensive state, GI hormone plasma levels are altered. For example, the basal plasma levels of amylin,[102] glucagon,[103] and insulin[104] are higher, but circulating ghrelin is lower in hypertensive than normotensive humans.[105] We have reported that plasma glucose and insulin levels are not different between salt-resistant and salt-sensitive hypertensive humans. However, oral glucose administration increases plasma insulin levels to a greater extent in salt-sensitive than salt-resistant subjects.[106] The fasting serum gastrin levels are similar in normotensive and hypertensive adult humans, but a mixed meal increased plasma gastrin to greater levels in hypertensive patients than normotensive controls.[107] We have suggested that the greater increase in plasma gastrin in hypertensive than normotensive subjects may be a compensatory response to the impaired natriuretic effect of gastrin, if the studies in the SHRs could be translated to hypertensive humans. In addition, antihypertensive medications also alter circulating GI hormone concentrations.[102,108] It is still unknown what mechanisms produce different GI hormone levels between normotensive and hypertensive status. However, recent studies showed that the inherent differences in gut architecture between WKY rats and SHRs may lead to changes of gut hormones. SHR proximal colon has a mean steady-state modulus almost 3 times greater than WKY rat colon, which is associated with an increase in the vascular smooth muscle cells layer and collagen deposition in the intestinal wall in SHRs.[109] Moreover, the increase in blood pressure in SHRs is also associated with gut pathology such as increasing intestinal permeability and decreasing tight junction proteins.[110] These phenomena that cause stiffening in relation to changes of gut hormones and hypertension is

**Table.** Summary of Gut-Derived Hormones, Their Receptors, and Functions in Animals and in Renal Cells

| Hormone/Peptide | Source | Receptor | Receptor Type | Renal Function in Animals | Renal Site of Hormone Actions | Function in Renal Cells |
|---|---|---|---|---|---|---|
| **Promotes natriuresis** | | | | | | |
| Amylin | Pancreas | Amylin receptor | GPCR | Increases sodium excretion, GFR, and RPF in anesthetized rats[70] | Proximal tubule, distal nephron, juxtaglomerular apparatus | Stimulates proliferation of primary RPT cells from SD rats[71] |
| Glucagon | Pancreas | Glucagon receptor | GPCR | Inhibits the reabsorption of water and $Na^+$ in hormone-deprived rats[72] | Proximal tubule | Acutely (1 hour) inhibits, but chronically (24 hours) activates NHE3 activity in OKP cells[73] |
| Gastrin | Stomach | CCKAR, CCKBR | GPCR | Induces natriuresis and diuresis in WKY rats but not SHRs[11,74] | Proximal tubule | Inhibits NKA and NHE3 activity in RPT cells from WKY rats and human[11,75] |
| Ghrelin | Stomach | GHSR | GPCR (GHSR1a), a 5-transmembrane spanning form, GHSR1b | Promotes diuresis and renal nitric oxide production in Dahl salt-sensitive hypertensive rats[76], stimulates distal nephron-dependent sodium reabsorption in SD rats[77] | Distal nephron | Reduces mitochondria membrane potential and mitochondria-derived ROS, ameliorates Ang II-induced cell senescent in RPT cells (HK-2 cell line)[78] |
| CCK | Duodenum | CCKAR, CCKBR | GPCR | Induces diuresis and natriuresis in anesthetized SHRs[79] | Proximal tubule | ... |
| Uroguanylin | Duodenum and jejunum | Guanylate cyclase-C | Guanylyl cyclase family | Induces natriuresis, kaliuresis, and diuresis in male Wistar rats[80]; inhibits bicarbonate reabsorption in male Wistar rats[81,82] | Proximal tubule, renal distal tubule | Inhibits the NHE3 activity in RPT cells (LLC-PK$_1$ cell line)[81] and $H^+$-ATPase activity and surface expression in MDCK-C11 cells[82] |
| Guanylin | Duodenum and colon | Guanylate cyclase-C | Guanylyl cyclase family | Causes kaliuresis and diuresis with less pronounced natriuretic effect in male Wistar rats[80] | Collecting duct | Inhibits luminal $K^+$ channels in human CCD cells[83] |
| Secretin | Duodenum and jejunum | Secretin receptor | GPCR | Increases both urinary volume and sodium excretion in healthy male volunteers[84] | Thick ascending limb of the loop of Henle | ... |
| VIP | The whole small intestine | VIP receptor | GPCR | Increases the excretion of sodium, chloride, potassium, and fluid in male SD rats[85] | Proximal tubules | Decreases the intracellular ROS levels in HK2 human renal cells[86], stimulates adenylate cyclase activity in canine renal epithelial (MDCK) cells[87] |
| GLP-1 | Distal small intestine | GLP-1 receptor | GPCR | Inhibits sodium uptake, facilitates natriuresis in male Wistar rats[88] | The brush border of proximal tubules | Inhibits the NHE3 activity and sodium reabsorption in RPT cells (LLC-PK$_1$ cell line) and primary porcine RPT cells[89,90] |

Continued

**Table.** Continued

| Hormone/Peptide | Source | Receptor | Receptor Type | Renal Function in Animals | Renal Site of Hormone Actions | Function in Renal Cells |
|---|---|---|---|---|---|---|
| PYY | Intestinal mucosa of the ileum and large intestine | Y receptors (Y1-Y5) | GPCR | Increases sodium excretion, decreases GFR and RBF in male subjects and Wistar rats[91,92] | Proximal tubules | Stimulates cell growth of mouse RPT cells[93] |
| Promotes sodium retention | | | | | | |
| Insulin | Pancreas | Insulin receptor | Tyrosine kinase receptor | Stimulates sodium and volume absorption in the rabbit kidney[94] | RPTs, the TALH, the distal convoluted tubule and the connecting tubule | Stimulates sodium transporters including NKA and NHE3 in OK cells and in primary RPT cells from SD rats[95,96] |
| C-peptide | Pancreas | … | … | Attenuates high salt-induced urine albumin, glomerular permeability, renal inflammation in the Dahl salt-sensitive rat[97] | Proximal tubules, medullary thick ascending limb | Stimulates NKA in human RPT cells[98] |
| IGF-1 | Liver | IGF receptor | Tyrosine kinase receptor | Increases GFR and RPF, and decreases renal vascular resistance in WKY rats, but not in SHRs[99], inhibits the basolateral Cl channels in SD rats[100] | RPT, thick ascending limb collecting ducts | Stimulates ClC-K2 channels, promotes net $Na^+$ and $Cl^-$ reabsorption in mouse CCD cells[101] |

Ang II indicates angiotensin II; CCD, cortical collecting ducts; CCKAR, cholecystokinin A receptor; CCKBR, cholecystokinin B receptor; GFR, glomerular filtration rate; GHSR, growth hormone secretagogue receptor; GLP-1, glucagon-like peptide-1; GPCR, G-protein coupled receptor; IGF, insulin-like growth factor; MDCK, Madin-Darby canine kidney; NHE3, $Na^+$-$H^+$ exchanger 3; NKA, $Na^+$-$K^+$-ATPase; OKP cells, opossum kidney proximal tubule cells; PYY, peptide YY; RBF, renal blood flow; ROS, reactive oxygen species; RPF, renal plasma flow; RPT, renal proximal tubule; SD rats, Sprague-Dawley rats; SHRs, spontaneously hypertensive rats; TALH, thick ascending limb of Henle; VIP, vasoactive intestinal peptide; WKY rats, Wistar Kyoto rats.

unknown. However, these changes in gut pathology in hypertension are associated with alterations of gut microbiota,[110] which has been reported to play an important role in the regulation of gut or renal hormones/peptides (vide infra).

In the kidney, there are also differences of GI hormone levels and their receptor expression and function between the hypertensive and normotensive state. For example, renal amylin receptor expression is increased[111] but renal glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) expression is decreased in SHRs and hypertensive patients.[112] The renal expression of insulin receptors is not different between WKY and SHRs, but a high-salt diet decreases insulin receptor expression in WKY but not SHRs.[113] Of note is that insulin-resistant rats have decreased renal insulin expression.[114] We have reported that there is no difference of cell surface membrane expression of gastrin receptor, also called cholecystokinin (CCK) B receptor (CCKBR), in RPT cells between WKY rats and SHRs. However, the infusion of gastrin induces a natriuresis and diuresis in WKY rats but not in SHRs.[11] Gastrin inhibits $Na^+$-$K^+$-ATPase activity in RPT cells from WKY rats but not SHRs.[11] However, gastrin-containing cells are increased in the stomach of SHRs and rats with renovascular hypertension.[115,116]

In this report, we only discuss 2 GI hormones, gastrin and GLP-1, which have received increasing attention because of their ability to regulate renal sodium handling and blood pressure, by themselves and in interaction with other hormones.

## Glucagon-Like Peptide-1

GLP-1 is secreted by intestinal L-cells. Under normal conditions, GLP-1 is rapidly degraded at the N-terminal penultimate position by dipeptidyl peptidase-4. There is no difference in circulating levels of GLP-1 between young (5-week-old) WKY and SHRs. However, there is a nonsignificant trend towards a decrease in plasma levels of total GLP-1 in adult (20-week-old) SHRs compared to adult WKY rats, which may be because of the higher plasma level and activity of dipeptidyl peptidase-4 in SHRs than age-matched WKY rats.[117] The actions of GLP-1 are primarily mediated by its receptor GLP-1R, which is widely distributed throughout the body, including the kidney. GLP-1R is expressed in the brush border of RPT. In rodents, GLP-1R stimulation suppresses RPT sodium transport, resulting in a natriuresis,[88] which is also aided by GLP-mediated increase in glomerular filtration rate in rodents. GLP-1R is constitutively active because the intravenous administration of exendin-9, a GLP-1R antagonist, decreased glomerular filtration rate, lithium clearance, urine flow, and sodium excretion in male Wistar rats. The inhibition of RPT sodium transport by GLP-1 is caused by inhibition of NHE3 activity via a protein kinase A–dependent mechanism.[88] GLP-1R expression is decreased in

renal arteries of SHRs and hypertensive patients.[112] GLP-1R antagonist exendin 9 to 39 inhibits GLP-1R-mediated relaxation in WKY arteries, whereas the relaxations are significantly less in SHR arteries.[112] GLP-1 has antihypertensive effects that may be related to both an increase in sodium excretion and vasodilatory effect in rodents.[118]

In humans, as in rodents, GLP-1 induces natriuresis in healthy subjects and in insulin-resistant obese men.[119,120] GLP-1-mediated natriuresis in humans is related to inhibition of renal proximal sodium transport.[119] However, in contrast to rodents, the natriuretic effect of GLP-1 is not associated with an increase in renal plasma flow or glomerular filtration rate.[119,120] The natriuretic effect of GLP-1 in humans is also associated with a decrease in plasma Ang II but not plasma renin, aldosterone, or urinary excretion of angiotensinogen.[119] The natriuretic and antihypertensive effect of exendin-4, a GLP-1 agonist, is also related to a decrease in renal Ang II concentration in salt-sensitive obese db/db mice.[121] Exendin-4 also prevents Ang II-induced hypertension in nondiabetic mice.[121] A synergism between GLP-1 and atrial natriuretic peptide is found in rodents but not in humans.[122] In a 24-week, double-blind, placebo-controlled, parallel-group study at 23 centers, exenatide, a GLP-1 agonist, reduced systolic and diastolic blood pressure.[123] Similar results were found with ambulatory blood pressure.[124] A meta-analysis of clinical trials including 16 randomized controlled trials that enrolled 3443 patients showed that treatment with the GLP-1R agonist reduced systolic and diastolic blood pressure in patients with type 2 diabetes.[125] Another meta-analysis also showed a beneficial effect of GLP-1R agonists on major cardiovascular events.[126]

The above studies would suggest that GLP-1 would have an antihypertensive action. Indeed, in humans and mice GLP-1 has antihypertensive effects.[124,127,128] However, several studies in rats have reported that GLP-1 injection increases blood pressure in a short time.[129,130] The reason may be associated with the fact that GLP-1 also acutely increases heart rate and cardiac output, and activates autonomic regulatory neurons.[129,131] Plasma levels of GLP-1 have been associated with systolic and diastolic blood pressure in awake and sleeping healthy human subjects.[132] The positive correlation between plasma GLP-1 and blood pressure was not related to blood glucose or insulin but could be related to insulin resistance.

Decreased GLP-1 and renal GLP-1R expression may be involved in the pathogenesis of hypertension. As stated above, renal arteries from SHRs and humans with essential hypertension have decreased GLP-1Rs, and GLP-1-mediated renal arterial vasorelaxation is impaired in SHRs.[112] In rats, serum level of GLP-1, as well as renal GLP-1R expression, is decreased in N(G)-nitro-L-arginine methyl ester (L-NAME)-induced hypertension, relative to controls.[133] Sitagliptin, a dipeptidyl peptidase-4 inhibitor, protects against L-NAME-

induced hypertensive nephropathy by increasing the serum level of GLP-1 and upregulation of GLP-1 receptors.[133]

## CCK and Gastrin

Gastrin is mostly synthetized in the G cells in the mucosa of the gastric antrum. Small amounts are produced in the mucosa of the jejunum and outside the GI tract, such as a few cerebral and peripheral neurons, pituitary gland, and spermatocytes.[134–136] CCK, unlike gastrin, is synthesized by I cells in the upper intestine, but share the same receptors, CCK receptor type A (CCKAR) and CCKBR. CCKAR is characterized by a high affinity for CCK and by a low affinity for gastrin; in contrast, CCKBR has a similar affinity for both peptide hormones. Because plasma gastrin levels are much higher than CCK, CCKBR is also considered a gastrin receptor.[137] The CCKBR is expressed in specific nephron segments, including the proximal tubule, distal tubules, and collecting ducts.[74,138] We have reported that CCKBR mRNA but not CCKAR is expressed in human RPT cells.[75] In the isolated perfused rat kidney, it is the CCKBR, not CCKAR, that mediates the increase in sodium and decrease in potassium excretion caused by the infusion of gastrin-17.[74]

Both CCK and gastrin induce natriuresis and diuresis.[11,74,79,134] CCK may not increase glomerular filtration rate[79] but can increase renal blood flow that is blunted in obese-prone and hypertensive rats.[139] Although both CCK and gastrin exert similar effects in kidney, circulating gastrin levels are 10- to 20-fold higher than CCK.[140] Circulating CCK levels are not or transiently increased by gastric distention or duodenal saline infusion.[141] Moreover, CCK in the circulation is rapidly degraded by aminopeptidases.[142] Of all the gut hormones, gastrin is the one that is taken up to the greatest extent by RPTs.[143] Food (with $Na^+$) increases serum gastrin levels, and $Na^+$ given orally, even without food, also increases serum gastrin levels.[144] Therefore, gastrin may be a better candidate than CCK as the effector of the gastro-renal reflex, at least regarding sodium balance.

The importance of gastrin in the regulation of sodium excretion and blood pressure is also supported by the gastrin (Gast) gene-deficient mice ($Gast^{-/-}$). $Gast^{-/-}$ mice do not increase their sodium excretion after ingestion of sodium and develop salt-sensitive hypertension.[145] We and others have reported the diuretic and natriuretic effects of gastrin in both rats and humans.[11,74,134,146] This may be related to the ability of gastrin to inhibit $Na^+$-$K^+$-ATPase and NHE3 activities in RPT cells.[11,75,147] Moreover, the inhibition of renal sodium transport by gastrin may be tissue specific because gastrin increases $H^+$-$K^+$-ATPase activity in gastric parietal cells.[148] Our studies also showed that the diuretic and natriuretic effects of gastrin, as well as its inhibitory effect on $Na^+$-$K^+$-ATPase activity, are lost in SHRs, suggesting that aberrant

regulation of gastrin on the natriuresis may have a role in the pathogenesis of hypertension.[11,149] The fasting serum gastrin levels are similar in normotensive and hypertensive adults; however, the increase of serum gastrin levels is higher in the latter group than in the former group after a mixed meal.[107]

## Effects of Bariatric Surgery on the Secretion of GI-Derived Hormones and Blood Pressure

Bariatric surgery may affect the secretion of gut-derived hormones and blood pressure. Different surgical methods may have different effects on the secretion of the same GI hormone. For example, fasting plasma gastrin levels are normal in laparoscopic gastric bypass surgery,[150] while sleeve gastrectomy results in increased fasting plasma gastrin levels.[151] The postprandial gastrin secretion induced by a mixed meal is also enhanced by sleeve gastrectomy.[152] By contrast, procedures that reroute the nutrient passage to the intestines, bypassing the gastric antrum, such as Roux-en-Y gastric bypass (RYGB), prevent the increase in plasma gastrin following a mixed meal.[152–154]

Depending on the subjects or postoperative time, bariatric surgery has different effects on the GI hormone responses. The first 2 weeks after RYGB in obese nondiabetic subjects, fasting plasma levels of insulin, ghrelin, and peptide YY (PYY) are decreased, but insulin sensitivity increased.[153] The postprandial response to a mixed meal is increased for C-peptide, GLP-1, GLP-2, PYY, CCK, and glucagon; by contrast, the postprandial response was decreased for ghrelin, leptin, and gastrin and unchanged for glucose-dependent insulinotropic polypeptide, amylin, pancreatic polypeptide, and somatostatin.[153] In obese patients with type 2 diabetes, 15 days after RYGB, fasting plasma levels of pancreatic polypeptide, glucagon, and GLP-1 are increased; but the pancreatic polypeptide response to a mixed meal is decreased while that of glucagon and GLP-1 remains increased.[155] After 1 year in these same patients, PYY response to a mixed meal is increased, while amylin, ghrelin, and GLP-1 are decreased.[155] The same study also found that the hormonal responses after sleeve gastrectomy are similar to those with RYGB except that fasting and meal-induced plasma pancreatic polypeptide levels remain increased but unchanged for amylin.[155]

Both long-term and short-term studies have shown that the blood pressures are decreased in adults and adolescents who underwent bariatric surgery, such as RYGB and sleeve gastrectomy.[156–158] Compared with RYGB, sleeve gastrectomy is associated with better early remission rates for hypertension and improvement in insulin sensitivity.[159,160] This may be related to the ability of bariatric surgery to increase the plasma levels of natriuretic enterokines such as GLP-1,[155,160,161] which is natriuretic.[88,118,119] In a study of 33 patients that lasted for 14 to 41 months after RYGB, 11 had

increased sodium excretion while 22 had decreased sodium excretion that was related to "excess weight loss" and could also have been related to decreased sodium intake.[162,163] Rats that are undergoing RYGB surgery also have increased sodium excretion following oral salt loading.[164] The decrease in glomerular filtration from high values with bariatric surgery could also be considered a beneficial rate.[165,166]

## Interaction Between GI and Renal Hormones in the Regulation of Blood Pressure

Depending on the state of sodium balance, an oral NaCl load may induce a greater natriuresis and diuresis than an intravenous infusion of the same amount of NaCl in some but not all studies.[35–38] As stated above, the negative studies should not be taken to dispute the presence of a "gastro-renal axis" because there are sodium and chloride sensors[167] outside the GI tract and kidney (eg, vascular smooth muscles, heart, and nervous system) that "instruct" the kidney to decrease sodium transport.[29,168,169]

## Interaction Between GI Hormones and Renal Dopamine

Dopamine, a neurotransmitter in neural tissue, also acts as an autocrine/paracrine substance in nonneural tissues including the kidney. Dopamine, produced locally in the kidney, is now recognized to serve an important role in the regulation of blood pressure and sodium balance by direct actions on renal and intestinal epithelial ion transport, interaction with other receptors, and modulation of the secretion of hormonal/humoral agents.[26,170–174] Dopamine receptors are classified into $D_1$- and $D_2$-like receptor subtypes: $D_1$-like receptors ($D_1R$ and $D_5R$) couple to stimulatory G protein $G\alpha S$ and stimulate adenylyl cyclase activity, whereas $D_2$-like receptors ($D_2R$, $D_3R$, and $D_4R$) couple to inhibitory G protein $G\alpha i/G\alpha o$ and inhibit adenylyl cyclase activity. These receptors can also couple to other G protein subunits, including Gq and Golf.[175–177] All of the 5 dopamine receptor subtypes are expressed in the nephron. Disruption of any of the dopamine receptor genes in mice results in hypertension, the pathogenesis of which is specific for each receptor subtype.[173] In hypertensive states, dopamine receptor–mediated natriuresis and diuresis are impaired. The dopaminergic effect on renal water and sodium transport is modulated by interaction with GI hormones (vide infra).

## CCK/Gastrin and Dopamine Interaction

Gastrin is the major GI hormone taken up by RPT cells.[143] Disruption of gastrin receptor (CCKBR) in mice caused hypertension and decreased sodium excretion.[178] We tested the hypothesis that gastrin may interact with renal dopamine receptors to increase sodium excretion, an impairment of which may result in hypertension.[11,178] We found that gastrin synergistically interacts with renal $D_1$-like receptors to increase water and sodium excretions in normotensive WKY rats, effects that were not observed in SHRs. The interaction between gastrin and dopamine in the kidney occurred at the receptor level because blockade of $D_1$-like or CCKBR abolished the natriuresis and diuresis caused by gastrin or $D_1$-like receptor agonist fenoldopam, in WKY rats and BALB/c mice.[11,178] The gastrin/$D_1$-like receptor interaction was confirmed in RPT cells. In RPT cells from WKY but not SHRs, stimulation of either $D_1$-like receptor or CCKBR inhibited $Na^+$-$K^+$-ATPase activity, an effect that was blocked by $D_1$-like receptor or CCKBR antagonist.[11] We also found that CCKBR colocalized and coimmunoprecipitated with $D_1R$ or $D_5R$ in RPT cells, which was increased after stimulation of either $D_1$-like receptor agonist or gastrin.[11,178] Moreover, stimulation of 1 receptor increased the RPT cell membrane expression of the other receptor, effects that were not observed in SHRs.[11] The natriuresis induced by a high sodium diet can also be blocked by $D_1$-like receptor agonist or CCKBR antagonist.[178] These data suggest that there is a synergism between $CCK_BR$ and $D_1R$ or $D_5R$ to increase sodium excretion. An aberrant interaction between the renal $CCK_BR$ and both $D_1$-like receptors may play a role in the pathogenesis of hypertension.

## Insulin and Renal Dopamine Interaction

Insulin is secreted from pancreatic β cells, and exerts its physiological functions via its receptors. Insulin receptors are widely distributed in the kidney and affect multiple aspects of renal function. Besides its action on glucose metabolism, insulin acts on almost all of the nephron segments and has been associated with anti-natriuresis at the whole-animal level, sodium retention in isolated, perfused tubule studies, and sodium uptake in cell culture.[179–181] In kidney, insulin stimulates sodium and volume absorption by directly stimulating some specific sodium transporters, exchangers, and channels in renal tubule segments.[179–181] Compensatory hyperinsulinemia in individuals with insulin resistance enhances salt absorption in the RPT, resulting in a state of salt overload and hypertension. On the other hand, a high sodium diet causes an increase in insulin resistance.[182]

Insulin and dopamine have counterregulatory effects on renal sodium transport. Insulin interacts with dopaminergic system at 2 different levels in the kidney. First, insulin positively regulates the uptake of L-dihydroxyphenylalanine, the immediate precursor of catecholamines, including dopamine, through the increase in the number of high-affinity transport sites in the RPT.[183] Second, insulin impairs

dopamine receptor expression and function in the kidney. Studies in both RPTs from hyperinsulinemic animals and renal cell cultures treated with insulin show reduced $D_1R$ number, defective receptor-G protein coupling, and blunted $D_1$-like agonist-induced $Na^+$-$K^+$-ATPase inhibition.[184,185] Moreover, insulin resistance leads to hyperphosphorylation of $D_1R$ and their uncoupling from Gs proteins in obese Zucker rats, which can be restored by an insulin sensitizer, rosiglitazone.[186] It is possible that the insulin-mediated increase in RPT cell uptake of L-dihydroxyphenylalanine could be a compensatory mechanism for the insulin-mediated blunting of $D_1R$ function.

In addition to the interaction between insulin and $D_1R$, insulin also interacts with $D_5R$ and $D_2R$. Insulin increases $D_5R$ expression and its mediated inhibition of $Na^+$-$K^+$-ATPase activity in RPT cells, which may be an important counterbalance to the increase in renal tubular sodium reabsorption induced by insulin. However, the compensatory increase in $D_5R$ expression following insulin treatment is lost in RPT cells from SHRs.[187] Dopamine also regulates insulin receptor expression and function. Thus, the $D_1$-like receptor agonist fenoldopam increases the expression of insulin receptor in human RPT cells. Moreover, $D_1R$ interacts with sorting nexin 5 to increase the sensitivity to insulin via a positive regulation of insulin receptor expression and insulin signaling.[188] Additionally, activation of $D_2R$ also regulates insulin secretion. Acute administration of a $D_2$-like receptor agonist quinpirole or an agonist bromocriptine inhibits glucose-stimulated insulin secretion by a $D_2R$-dependent or -independent mechanism.[189,190] Disruption of the $D_2R$ in mice also shows the impaired insulin secretion and glucose intolerance.[191]

## Interaction Between GI Hormones and the RAS

It is well known that the RAS plays a key role in the development and maintenance of hypertension.[192,193] The classical view of the products of the RAS as a circulating hormone has evolved to organ-based systems that perform paracrine/autocrine functions. Local RAS exists in different organs including the kidney. Ang II is classically considered the main mediator of the RAS. The renal tubules and interstitial compartments contain much higher levels of Ang II than plasma.[194] The majority of intrarenally produced Ang II functions as a paracrine hormone. $AT_1R$ mediates the vast majority of renal actions of Ang II, including renal tubular sodium transport.[27] The RAS is broadly activated in hypertensive status, including increased angiotensin-converting enzyme activity and Ang II levels in plasma, and enhanced renal $AT_1R$ expression and intrarenally generated Ang II.[195,196] The counteraction of some endogenous factors may be novel therapies to combat RAS-dependent hypertension. There are increasing evidences of interactions between intrarenal RAS and the GI-derived hormones in the kidney.

## GLP-1 and the RAS

GLP-1 can interact with the RAS.[119,121,122] GLP-1R agonists counteract the hypertensive action of Ang II. Rodent studies have shown that GLP-1R stimulation ameliorates Ang II-induced hypertension.[121,122] Exendin-4, a GLP-1R agonist, attenuated Ang II-induced high-salt sensitivity and minimized the increase in blood pressure caused by Ang II infusion.[121] Another GLP-1R agonist, liraglutide, also normalized both systolic and diastolic blood pressure in mice with Ang II-induced hypertension.[122] Exendin-4 was also reported to decrease the Ang II-induced ERK1/2 phosphorylation in opossum RPT cells.[121]

There is also evidence of a renal beneficial role of the combination of GLP-1R agonists with inhibitors of the RAS components, such as angiotensin-converting enzyme inhibitors and Ang II receptor blockers. An exenatide analog, AC3174, lowered blood pressure in Dahl salt-sensitive rats fed a high-salt diet. Moreover, the ability of AC3174 to attenuate renal damage was enhanced by captopril, an angiotensin-converting enzyme inhibitor, in these Dahl salt-sensitive rats that were fed a high salt diet.[197] The combination of an Ang II receptor blocker (telmisartan) and a dipeptidyl peptidase-4 inhibitor (linagliptin) reduced urinary albumin excretion and renal oxidative stress in diabetic endothelial nitric oxide synthase knockout mice, indicating that linagliptin in addition to an Ang II receptor blocker may be a new therapeutic approach for patients with diabetic nephropathy.[198]

A randomized, double-blinded, single-day, crossover trial showed that the infusion of GLP-1 in healthy young males decreased Ang II but not plasma renin or aldosterone levels or urinary excretion of angiotensinogen.[119] However, the intravenous administration of GLP-1 increased aldosterone secretion in rats.[199]

## The Role of Gut Microbiota in the Regulation of Gastro-Renal Axis and Blood Pressure

In recent years, an increasing number of studies have focused on the association between gut microbiota and cardiovascular diseases, including hypertension. There is a significant decrease in gut microbial richness, diversity, and evenness in addition to an increase in the Firmicutes/Bacteroidetes ratio in the SHRs and a small cohort of human hypertension patients.[200] The oral administration of minocycline attenuates high blood pressure, and rebalances the dysbiosis of gut microbiota in the Ang II infusion hypertension model by reducing the Firmicutes/Bacteroidetes ratio.[200] Similar differences of gut microbiotal genomic composition have been found between the Dahl salt-sensitive and Dahl salt-resistant rats.[201] High blood pressure is induced in WKY rats after

**Figure.** Schematic representation of the interaction of gut-derived hormones with renal hormones/peptides in the regulation of natriuresis and blood pressure. ACEI indicates angiotensin converting enzyme inhibitor; Ang II, angiotensin II; ARB, angiotensin II receptor blocker; CCKBR, cholecystokinin A receptor; $D_1R$, dopamine $D_1$ receptor; $D_5R$, dopamine $D_5$ receptor; GLP-1, glucagon-like peptide-1; GLP-1R, glucagon-like peptide-1 receptor; IR, insulin receptor; L-DOPA, L-dihydroxyphenylalanine; NHE3, $Na^+$-$H^+$ exchanger 3; NKA, $Na^+$-$K^+$-ATPase; RAS, renin–angiotensin system; RPT, renal proximal tubule.

exchanging the gut microbiota between the WKY rats and SHRs.[202] Gut microbial metabolites, such as short-chain fatty acids (SCFAs), were found to influence host physiological functions including blood pressure.[203] SCFAs influence blood pressure via activating sensory receptors such as olfactory receptor 78 (Olfr78), GPR41, and GPR43.[203,204] Olfr78 is expressed well in the renal juxtaglomerular apparatus, where activation of Olfr78 induces renin secretion. Treatment with antibiotics reduces the biomass of the gut microbiota and elevates blood pressure in Olfr78 knockout mice.[205] These studies indicate the role of gut microbiota in the pathophysiology of hypertension.

Although the mechanisms of gut microbiota on regulation of blood pressure are complex, effects on gut or renal hormones/peptide synthesis or release might be involved. The gut microbiota, via various metabolites such as SCFA, can influence the number and function of enterochromaffin cells, thereby promoting the release of serotonin that in turn impacts host physiological functions.[206] It is reported that gut microbiota affect the generation of free dopamine and norepinephrine in the gut lumen.[207] The levels of dopamine and norepinephrine in the lumen of the cecum are higher in control mice than the germ-free mice.[207] The absence of the gut microbiota has been reported to exacerbate the neuroendocrine and behavioral responses to acute stress and decreased dopamine turnover in the frontal cortex, hippocampus, and striatum in response to acute stress in F344 rats.[208] However, in BALB/c mice, administration of oral antimicrobials increases exploratory behavior that is independent of

changes in levels of GI neurotransmitters such as serotonin, dopamine, and norepinephrine.[209] In addition, SCFAs, via activation of Olfr78, induce renin release from the afferent arteriole and increase blood pressure, which is confirmed in Olfr78-deficient mice displaying lower renin concentrations, and decreased blood pressure.[205] Resistant starch is fermented to SCFAs by microflora in the large intestine. High-amylose resistant starch is associated with increased gene expression of proglucagon (gene for GLP-1) and PYY in the cecal and large intestine, and increased plasma levels of PYY and GLP-1, which play important roles in the regulation of blood pressure.[210] Dietary factors such as high fiber diet, and acetate supplementation change the gut microbiota, downregulate renal RAS, and prevent the development of hypertension in desoxycorticosterone acetate–salt hypertensive mice.[211] These indicate that targeting the gut microbiota may be a potential and novel strategy for the regulation of gastro-renal axis and treatment of hypertension.

## Conclusions and Perspectives

In summary, increasing evidences support the concept of a gastro-renal communication in the excretion of a sodium load. Enterokines are released from the intestine into the circulation in response to sodium intake that interacts with dopamine receptors in the kidney to regulate sodium excretion and keep the blood pressure in the normal range (Figure). The aberrant gastro-renal natriuretic signaling axis may be involved in the pathogenesis of hypertension.

Increased understanding of the role of the gastro-renal axis in the regulation of renal function may give us a novel insight into the pathogenesis of hypertension and provide a new treatment strategy for hypertension.

## Sources of Funding

## Disclosures

No conflicts of interest, financial or otherwise, are declared by the authors.

## References

1. Poulter NR, Prabhakaran D, Caulfield M. Hypertension. *Lancet*. 2015;386:801–812.

2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. *Lancet*. 2005;365:217–223.

3. US Burden of Disease Collaborators. The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. *JAMA*. 2013;310:591–608.

4. Whelton PK, Appel LJ, Sacco RL, Anderson CA, Antman EM, Campbell N, Dunbar SB, Frohlich ED, Hall JE, Jessup M, Labarthe DR, MacGregor GA, Sacks FM, Stamler J, Vafiadis DK, Van Horn LV. Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations. *Circulation*. 2012;126:2880–2889.

5. Farquhar WB, Edwards DG, Jurkovitz CT, Weintraub WS. Dietary sodium and health: more than just blood pressure. *J Am Coll Cardiol*. 2015;65:1042–1050.

6. Lambers Heerspink HJ, Holtkamp FA, Parving HH, Navis GJ, Lewis JB, Ritz E, de Graeff PA, de Zeeuw D. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. *Kidney Int*. 2012;82:330–337.

7. He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. *BMJ*. 2013;346:f1325.

8. Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. *Cochrane Database Syst Rev*. 2011;11:CD004022.

9. Furness JB, Rivera LR, Cho HJ, Bravo DM, Callaghan B. The gut as a sensory organ. *Nat Rev Gastroenterol Hepatol*. 2013;10:729–740.

10. Michell AR, Debnam ES, Unwin RJ. Regulation of renal function by the gastrointestinal tract: potential role of gut-derived peptides and hormones. *Annu Rev Physiol*. 2008;70:379–403.

11. Chen Y, Asico LD, Zheng S, Villar VA, He D, Zhou L, Zeng C, Jose PA. Gastrin and $D_1$ dopamine receptor interact to induce natriuresis and diuresis. *Hypertension*. 2013;62:927–933.

12. Herrera M, Coffman TM. The kidney and hypertension: novel insights from transgenic models. *Curr Opin Nephrol Hypertens*. 2012;21:171–178.

13. Curtis JJ, Luke RG, Dustan HP, Kashgarian M, Whelchel JD, Jones P, Diethelm AG. Remission of essential hypertension after renal transplantation. *N Engl J Med*. 1983;309:1009–1015.

14. Bianchi G, Fox U, Di Francesco GF, Giovanetti AM, Pagetti D. Blood pressure changes produced by kidney cross-transplantation between spontaneously hypertensive rats and normotensive rats. *Clin Sci Mol Med*. 1974;47:435–448.

15. Morgan DA, DiBona GF, Mark AL. Effects of interstrain renal transplantation on NaCl-induced hypertension in Dahl rats. *Hypertension*. 1990;15:436–442.

16. Crowley SD, Gurley SB, Oliverio MI, Pazmino AK, Griffiths R, Flannery PJ, Spurney RF, Kim HS, Smithies O, Le TH, Coffman TM. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. *J Clin Invest*. 2005;115:1092–1099.

17. Asico L, Zhang X, Jiang J, Cabrera D, Escano CS, Sibley DR, Wang X, Yang Y, Mannon R, Jones JE, Armando I, Jose PA. Lack of renal dopamine $D_5$ receptors promotes hypertension. *J Am Soc Nephrol*. 2011;22:82–89.

18. Rettig R, Stauss H, Folberth C, Ganten D, Waldherr B, Unger T. Hypertension transmitted by kidneys from stroke-prone spontaneously hypertensive rats. *Am J Physiol*. 1989;257:F197–F203.

19. Hall JE, Granger JP, do Carmo JM, da Silva AA, Dubinion J, George E, Hamza S, Speed J, Hall ME. Hypertension: physiology and pathophysiology. *Compr Physiol*. 2012;2:2393–2442.

20. Wadei HM, Textor SC. The role of the kidney in regulating arterial blood pressure. *Nat Rev Nephrol*. 2012;8:602–609.

21. Burnier M, Bochud M, Maillard M. Proximal tubular function and salt sensitivity. *Curr Hypertens Rep*. 2006;8:8–15.

22. Horita S, Seki G, Yamada H, Suzuki M, Koike K, Fujita T. Roles of renal proximal tubule transport in the pathogenesis of hypertension. *Curr Hypertens Rev*. 2013;9:148–155.

23. Wang X, Armando I, Upadhyay K, Pascua A, Jose PA. The regulation of proximal tubular salt transport in hypertension: an update. *Curr Opin Nephrol Hypertens*. 2009;18:412–420.

24. Gildea JJ, Xu P, Carlson JM, Gaglione RT, Bigler Wang D, Kemp BA, Reyes CM, McGrath HE, Carey RM, Jose PA, Felder RA. The sodium-bicarbonate cotransporter NBCe2 (slc4a5) expressed in human renal proximal tubules shows increased apical expression under high-salt conditions. *Am J Physiol Regul Integr Comp Physiol*. 2015;309:R1447–R1459.

25. Romero MF. Molecular pathophysiology of SLC4 bicarbonate transporters. *Curr Opin Nephrol Hypertens*. 2005;14:495–501.

26. Zhang MZ, Harris RC. Antihypertensive mechanisms of intra-renal dopamine. *Curr Opin Nephrol Hypertens*. 2015;24:117–122.

27. Giani JF, Janjulia T, Taylor B, Bernstein EA, Shah K, Shen XZ, McDonough AA, Bernstein KE, Gonzalez-Villalobos RA. Renal generation of angiotensin II and the pathogenesis of hypertension. *Curr Hypertens Rep*. 2014;16:477.

28. Noda M, Hiyama TY. Sodium sensing in the brain. *Pflugers Arch*. 2015;467:465–474.

29. Orlov SN, Mongin AA. Salt-sensing mechanisms in blood pressure regulation and hypertension. *Am J Physiol Heart Circ Physiol*. 2007;293:H2039–H2053.

30. Titze J, Machnik A. Sodium sensing in the interstitium and relationship to hypertension. *Curr Opin Nephrol Hypertens*. 2010;19:385–392.

31. Jones A, Kainz D, Khan F, Lee C, Carrithers MD. Human macrophage SCN5A activates an innate immune signaling pathway for antiviral host defense. *J Biol Chem*. 2014;289:35326–35340.

32. Benos DJ. Sensing tension: recognizing ENaC as a stretch sensor. *Hypertension*. 2004;44:616–617.

33. Xu W, Hong SJ, Zhong A, Xie P, Jia S, Xie Z, Zeitchek M, Niknam-Bienia S, Zhao J, Porterfield DM, Surmeier DJ, Leung KP, Galiano RD, Mustoe TA. Sodium channel Nax is a regulator in epithelial sodium homeostasis. *Sci Transl Med*. 2015;7:312ra177.

34. Fu Y, Vallon V. Mineralocorticoid-induced sodium appetite and renal salt retention: evidence for common signaling and effector mechanisms. *Nephron Physiol*. 2014;128:8–16.

35. Carey RM. Evidence for a splanchnic sodium input monitor regulating renal sodium excretion in man. Lack of dependence upon aldosterone. *Circ Res*. 1978;43:19–23.

36. Andersen LJ, Jensen TU, Bestle MH, Bie P. Gastrointestinal osmoreceptors and renal sodium excretion in humans. *Am J Physiol Regul Integr Comp Physiol*. 2000;278:R287–R294.

37. Mironova E, Chen Y, Pao AC, Roos KP, Kohan DE, Bugaj V, Stockand JD. Activation of ENaC by AVP contributes to the urinary concentrating mechanism and dilution of plasma. *Am J Physiol Renal Physiol*. 2015;308:F237–F243.

38. Preston RA, Afshartous D, Forte LR, Rodco R, Alonso AB, Garg D, Raij L. Sodium challenge does not support an acute gastrointestinal-renal natriuretic signaling axis in humans. *Kidney Int*. 2012;82:1313–1320.

39. Drummond HA, Grifoni SC, Jernigan NL. A new trick for an old dogma: ENaC proteins as mechanotransducers in vascular smooth muscle. *Physiology (Bethesda)*. 2008;23:23–31.

40. Oka Y, Butnaru M, von Buchholtz L, Ryba NJ, Zuker CS. High salt recruits aversive taste pathways. *Nature*. 2013;494:472–475.

41. Liu X, Gu F, Jiang L, Chen F, Li F. Expression of bitter taste receptor Tas2r105 in mouse kidney. *Biochem Biophys Res Commun*. 2015;458:733–738.

42. Rajkumar P, Aisenberg WH, Acres OW, Protzko RJ, Pluznick JL. Identification and characterization of novel renal sensory receptors. *PLoS One*. 2014;9: e111053.

43. Laugerette F, Gaillard D, Passilly-Degrace P, Niot I, Besnard P. Do we taste fat? *Biochimie*. 2007;89:265–269.

44. Steinert RE, Beglinger C. Nutrient sensing in the gut: interactions between chemosensory cells, visceral afferents and the secretion of satiation peptides. *Physiol Behav*. 2011;105:62–70.

45. Chandrashekar J, Kuhn C, Oka Y, Yarmolinsky DA, Hummler E, Ryba NJ, Zuker CS. The cells and peripheral representation of sodium taste in mice. *Nature*. 2010;464:297–301.

46. Bigiani A. Amiloride-sensitive sodium currents in fungiform taste cells of rats chronically exposed to nicotine. *Neuroscience*. 2015;284:180–191.

47. Treesukosol Y, Lyall V, Heck GL, DeSimone JA, Spector AC. A psychophysical and electrophysiological analysis of salt taste in Trpv1 null mice. *Am J Physiol Regul Integr Comp Physiol*. 2007;292:R1799–R1809.

48. Cai H, Cong WN, Daimon CM, Wang R, Tschöp MH, Sévigny J, Martin B, Maudsley S. Altered lipid and salt taste responsivity in ghrelin and GOAT null mice. *PLoS One*. 2013;8:e76553.

49. Baquero AF, Gilbertson TA. Insulin activates epithelial sodium channel (ENaC) via phosphoinositide 3-kinase in mammalian taste receptor cells. *Am J Physiol Cell Physiol*. 2011;300:C860–C871.

50. Shigemura N, Iwata S, Yasumatsu K, Ohkuri T, Horio N, Sanematsu K, Yoshida R, Margolskee RF, Ninomiya Y. Angiotensin II modulates salty and sweet taste sensitivities. *J Neurosci*. 2013;33:6267–6277.

51. Lin W, Finger TE, Rossier BC, Kinnamon SC. Epithelial Na$^+$ channel subunits in rat taste cells: localization and regulation by aldosterone. *J Comp Neurol*. 1999;405:406–420.

52. Rabin M, Poli de Figueiredo CE, Wagner MB, Antonello IC. Salt taste sensitivity threshold and exercise-induced hypertension. *Appetite*. 2009;52:609–613.

53. Okoro EO, Uroghide GE, Jolayemi ET. Salt taste sensitivity and blood pressure in adolescent school children in southern Nigeria. *East Afr Med J*. 1998;75:199–203.

54. Arguelles J, Diaz JJ, Malaga I, Perillan C, Costales M, Vijande M. Sodium taste threshold in children and its relationship to blood pressure. *Braz J Med Biol Res*. 2007;40:721–726.

55. Di Nicolantonio R, Mendelsohn FA, Hutchinson JS. Sodium chloride preference of genetically hypertensive and normotensive rats. *Am J Physiol*. 1983;245:R38–R44.

56. Fregly MJ. NaCl intake and preference threshold of spontaneously hypertensive rats. *Proc Soc Exp Biol Med*. 1975;149:915–920.

57. Ishiwatari Y, Bachmanov AA. NaCl taste thresholds in 13 inbred mouse strains. *Chem Senses*. 2012;37:497–508.

58. Bachmanov AA, Beauchamp GK, Tordoff MG. Voluntary consumption of NaCl, KCl, CaCl2, and NH4Cl solutions by 28 mouse strains. *Behav Genet*. 2002;32:445–457.

59. Michikawa T, Nishiwaki Y, Okamura T, Asakura K, Nakano M, Takebayashi T. The taste of salt measured by a simple test and blood pressure in Japanese women and men. *Hypertens Res*. 2009;32:399–403.

60. Kato A, Romero MF. Regulation of electroneutral NaCl absorption by the small intestine. *Annu Rev Physiol*. 2011;73:261–281.

61. Spencer AG, Labonte ED, Rosenbaum DP, Plato CF, Carreras CW, Leadbetter MR, Kozuka K, Kohler J, Koo-McCoy S, He L, Bell N, Tabora J, Joly KM, Navre M, Jacobs JW, Charmot D. Intestinal inhibition of the Na$^+$/H$^+$ exchanger 3 prevents cardiorenal damage in rats and inhibits Na$^+$ uptake in humans. *Sci Transl Med*. 2014;6:227ra36.

62. Pácha J. Sodium balance and jejunal ion and water absorption in Dahl salt-sensitive and salt-resistant rats. *Clin Exp Pharmacol Physiol*. 1998;25:220–224.

63. Soleimani M. Dietary fructose, salt absorption and hypertension in metabolic syndrome: towards a new paradigm. *Acta Physiol (Oxf)*. 2011;201:55–62.

64. Meneton P, Jeunemaitre X, de Wardener HE, MacGregor GA. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. *Physiol Rev*. 2005;85:679–715.

65. Vázquez CM, Coleto R, Zanetti R, Ruiz-Gutierrez V. Increased Na(+)-H+ exchanger activity in the ileal brush-border membrane of spontaneously hypertensive rats. *Cell Mol Life Sci*. 1997;53:442–446.

66. Abu-Ghefreh A, Khan I. A role of intestine in hypertension: mechanism of suppression of intestinal Na-H exchanger isoform-3 in spontaneously hypertensive rats. *Clin Exp Hypertens*. 2013;35:543–549.

67. Ledoussal C, Woo AL, Miller ML, Shull GE. Loss of the NHE2 Na(+)/H(+) exchanger has no apparent effect on diarrheal state of NHE3-deficient mice. *Am J Physiol Gastrointest Liver Physiol*. 2001;281:G1385–G1396.

68. Linz D, Wirth K, Linz W, Heuer HO, Frick W, Hofmeister A, Heinelt U, Arndt P, Schwahn U, Böhm M, Ruetten H. Antihypertensive and laxative effects by pharmacological inhibition of sodium-proton-exchanger subtype 3-mediated sodium absorption in the gut. *Hypertension*. 2012;60:1560–1567.

69. Lienhard D, Lauterburg M, Escher G, Frey FJ, Frey BM. High salt intake down-regulates colonic mineralocorticoid receptors, epithelial sodium channels and 11β-hydroxysteroid dehydrogenase type 2. *PLoS One*. 2012;7:e37898.

70. Vine W, Smith P, LaChappell R, Blase E, Young A. Effects of rat amylin on renal function in the rat. *Horm Metab Res*. 1998;30:518–522.

71. Harris PJ, Cooper ME, Hiranyachattada S, Berka JL, Kelly DJ, Nobes M, Wookey PJ. Amylin stimulates proximal tubular sodium transport and cell proliferation in the rat kidney. *Am J Physiol*. 1997;272:F13–F21.

72. de Rouffignac C, Elalouf JM, Roinel N. Glucagon inhibits water and NaCl transports in the proximal convoluted tubule of the rat kidney. *Pflugers Arch*. 1991;419:472–477.

73. Amemiya M, Kusano E, Muto S, Tabei K, Ando Y, Alpern RJ, Asano Y. Glucagon acutely inhibits but chronically activates Na(+)/H(+) antiporter 3 activity in OKP cells. *Exp Nephrol*. 2002;10:26–33.

74. von Schrenck T, Ahrens M, de Weerth A, Bobrowski C, Wolf G, Jonas L, Jocks T, Schulz M, Bläker M, Neumaier M, Stahl RA. CCKB/gastrin receptors mediate changes in sodium and potassium absorption in the isolated perfused rat kidney. *Kidney Int*. 2000;58:995–1003.

75. Liu T, Jose PA. Gastrin induces sodium-hydrogen exchanger 3 phosphorylation and mTOR activation via a phosphoinositide 3-kinase-/protein kinase C-dependent but AKT-independent pathway in renal proximal tubule cells derived from a normotensive male human. *Endocrinology*. 2013;154:865–875.

76. Aoki H, Nakata M, Dezaki K, Lu M, Gantulga D, Yamamoto K, Shimada K, Kario K, Yada T. Ghrelin counteracts salt-induced hypertension via promoting diuresis and renal nitric oxide production in Dahl rats. *Endocr J*. 2013;60:571–581.

77. Kemp BA, Howell NL, Gildea JJ, Keller SR, Padia SH. Intrarenal ghrelin receptors regulate ENaC-dependent sodium reabsorption by a cAMP-dependent pathway. *Kidney Int*. 2013;84:501–508.

78. Fujimura K, Wakino S, Minakuchi H, Hasegawa K, Hosoya K, Komatsu M, Kaneko Y, Shinozuka K, Washida N, Kanda T, Tokuyama H, Hayashi K, Itoh H. Ghrelin protects against renal damages induced by angiotensin-II via an antioxidative stress mechanism in mice. *PLoS One*. 2014;9:e94373.

79. Ladines CA, Zeng C, Asico LD, Sun X, Pocchiari F, Semeraro C, Pisegna J, Wank S, Yamaguchi I, Eisner GM, Jose PA. Impaired renal D(1)-like and D(2)-like dopamine receptor interaction in the spontaneously hypertensive rat. *Am J Physiol Regul Integr Comp Physiol*. 2001;281:R1071–R1078.

80. Fonteles MC, Greenberg RN, Monteiro HS, Currie MG, Forte LR. Natriuretic and kaliuretic activities of guanylin and uroguanylin in the isolated perfused rat kidney. *Am J Physiol*. 1998;275:F191–F197.

81. Lessa LM, Carraro-Lacroix LR, Crajoinas RO, Bezerra CN, Dariolli R, Girardi AC, Fonteles MC, Malnic G. Mechanisms underlying the inhibitory effects of uroguanylin on NHE3 transport activity in renal proximal tubule. *Am J Physiol Renal Physiol*. 2012;303:F1399–F1408.

82. da Silva Lima V, Crajoinas RO, Carraro-Lacroix LR, Godinho AN, Dias JL, Dariolli R, Girardi AC, Fonteles MC, Malnic G, Lessa LM. Uroguanylin inhibits H-ATPase activity and surface expression in renal distal tubules by a PKG-dependent pathway. *Am J Physiol Cell Physiol*. 2014;307:C532–C541.

83. Sindić A, Hirsch JR, Velic A, Piechota H, Schlatter E. Guanylin and uroguanylin regulate electrolyte transport in isolated human cortical collecting ducts. *Kidney Int*. 2005;67:1420–1427.

84. Viteri AL, Poppell JW, Lasater JM, Dyck WP. Renal response to secretin. *J Appl Physiol*. 1975;38:661–664.

85. Rosa RM, Silva P, Stoff JS, Epstein FH. Effect of vasoactive intestinal peptide on isolated perfused rat kidney. *Am J Physiol*. 1985;249(5 Pt 1):E494–E497.

86. Vacas E, Bajo AM, Schally AV, Sánchez-Chapado M, Prieto JC, Carmena MJ. Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells. *Peptides*. 2012;38:275–281.

87. Griffiths NM, Rugg EL, Simmons NL. Vasoactive intestinal peptide control of renal adenylate cyclase: in vitro studies of canine renal membranes and cultured canine renal epithelial (MDCK) cells. *Q J Exp Physiol*. 1989;74:339–353.

88. Farah LX, Valentini V, Pessoa TD, Malnic G, McDonough AA, Girardi AC. The physiological role of glucagon-like peptide-1 in the regulation of renal function. *Am J Physiol Renal Physiol*. 2016;310:F123–F127.

89. Carraro-Lacroix LR, Malnic G, Girardi AC. Regulation of Na$^+$/H$^+$ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. *Am J Physiol Renal Physiol*. 2009;297:F1647–F1655.

90. Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. *Regul Pept*. 2007;141:120–128.

91. Playford RJ, Mehta S, Upton P, Rentch R, Moss S, Calam J, Bloom S, Payne N, Ghatei M, Edwards R, Unwin R. Effect of peptide YY on human renal function. *Am J Physiol*. 1995;268:F754–F759.

92. Bischoff A, Avramidis P, Erdbrügger W, Münter K, Michel MC. Receptor subtypes Y1 and Y5 are involved in the renal effects of neuropeptide Y. *Br J Pharmacol*. 1997;120:1335–1343.

93. Voisin T, Bens M, Cluzeaud F, Vandewalle A, Laburthe M. Peptide YY receptors in the proximal tubule PKSV-PCT cell line derived from transgenic mice. Relation with cell growth. *J Biol Chem*. 1993;268:20547–20554.

94. Ito O, Kondo Y, Takahashi N, Kudo K, Igarashi Y, Omata K, Imai Y, Abe K. Insulin stimulates NaCl transport in isolated perfused MTAL of Henle's loop of rabbit kidney. *Am J Physiol*. 1994;267:F265–F270.

95. Fuster DG, Bobulescu IA, Zhang J, Wade J, Moe OW. Characterization of the regulation of renal Na$^+$/H$^+$ exchanger NHE3 by insulin. *Am J Physiol Renal Physiol*. 2007;292:F577–F585.

96. Banday AA, Asghar M, Hussain T, Lokhandwala MF. Dopamine-mediated inhibition of renal Na,K-ATPase is reduced by insulin. *Hypertension*. 2003;41:1353–1358.

97. Sawyer RT, Flynn ER, Hutchens ZM Jr, Williams JM, Garrett MR, Maric-Bilkan C. Renoprotective effects of C-peptide in the Dahl salt-sensitive rat. *Am J Physiol Renal Physiol*. 2012;303:F893–F899.

98. Galuska D, Pirkmajer S, Barrès R, Ekberg K, Wahren J, Chibalin AV. C-peptide increases Na, K-ATPase expression via PKC- and MAP kinase-dependent activation of transcription factor ZEB in human renal tubular cells. *PLoS One*. 2011;6:e28294.

99. Inishi Y, Katoh T, Okuda T, Yamaguchi T, Kurokawa K. Modulation of renal hemodynamics by IGF-1 is absent in spontaneously hypertensive rats. *Kidney Int*. 1997;52:165–170.

100. Wang L, Li W, Kong S, Wu P, Zhang C, Gu L, Wang M, Wang W, Gu R. Insulin-like growth factor-1 (IGF-1) inhibits the basolateral Cl channels in the thick ascending limb of the rat kidney. *Biochim Biophys Acta*. 2012;1823:1163–1169.

101. Zaika O, Mamenko M, Boukelmoune N, Pochynyuk O. IGF-1 and insulin exert opposite actions on ClC-K2 activity in the cortical collecting ducts. *Am J Physiol Renal Physiol*. 2015;308:F39–F48.

102. Kailasam MT, Parmer RJ, Tyrell EA, Henry RR, O'Connor DT. Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk. *J Hypertens*. 2000;18:1611–1620.

103. Hörl WH, Schaefer RM, Heidland A. Abnormalities of carbohydrate metabolism in spontaneously hypertensive rats. *Klin Wochenschr*. 1988;66:924–947.

104. Marzano L, Colussi G, Del Torre M, Sechi LA, Catena C. Relationships of plasma lipoprotein(a) levels with insulin resistance in hypertensive patients. *Metabolism*. 2014;63:1439–1446.

105. Mao Y, Tokudome T, Kishimoto I. Ghrelin and blood pressure regulation. *Curr Hypertens Rep*. 2016;18:15.

106. Yatabe MS, Yatabe J, Yoneda M, Watanabe T, Otsuki M, Felder RA, Jose PA, Sanada H. Salt sensitivity is associated with insulin resistance, sympathetic overactivity, and decreased suppression of circulating renin activity in lean patients with essential hypertension. *Am J Clin Nutr*. 2010;92:77–82.

107. Jiang X, Wang W, Ning B, Liu X, Gong J, Gan F, Gao X, Zhang L, Jose PA, Qin C, Yang Z. Basal and postprandial serum levels of gastrin in normotensive and hypertensive adults. *Clin Exp Hypertens*. 2013;35:74–78.

108. Hamada N, Nishi Y, Tajiri Y, Setoyama K, Kamimura R, Miyahara K, Nuruki N, Hosoda H, Kangawa K, Kojima M, Mifune H. Disrupted regulation of ghrelin production under antihypertensive treatment in spontaneously hypertensive rats. *Circ J*. 2012;76:1423–1429.

109. Stewart DC, Rubiano A, Santisteban MM, Shenoy V, Qi Y, Pepine CJ, Raizada MK, Simmons CS. Hypertension-linked mechanical changes of rat gut. *Acta Biomater*. 2016;45:296–302.

110. Santisteban MM, Qi Y, Zubcevic J, Kim S, Yang T, Shenoy V, Cole-Jeffrey CT, Lobaton GO, Stewart DC, Rubiano A, Simmons CS, Garcia-Pereira F, Johnson RD, Pepine CJ, Raizada MK. Hypertension-linked pathophysiological alterations in the gut. *Circ Res*. 2017;120:312–323.

111. Wookey PJ, Cao Z, van Geenen RC, Voskuil M, Darby IA, Komers R, Cooper ME. Increased density of renal amylin binding sites in experimental hypertension. *Hypertension*. 1997;30:455–460.

112. Liu L, Liu J, Gao Y, Ng CF, Yu X, Dou D, Huang Y. Protein kinase Cβ mediates downregulated expression of glucagon-like peptide-1 receptor in hypertensive rat renal arteries. *J Hypertens*. 2015;33:784–790.

113. Sechi LA. Mechanisms of insulin resistance in rat models of hypertension and their relationships with salt sensitivity. *J Hypertens*. 1999;17:1229–1237.

114. Tiwari S, Halagappa VK, Riazi S, Hu X, Ecelbarger CA. Reduced expression of insulin receptors in the kidneys of insulin-resistant rats. *J Am Soc Nephrol*. 2007;18:2661–2671.

115. Kasacka I, Majewski M. An immunohistochemical study of endocrine cells in the stomach of hypertensive rats. *J Physiol Pharmacol*. 2007;58:469–478.

116. Kasacka I, Piotrowska Z, Lewandowska A. Alterations of rat stomach endocrine cells under renovascular hypertension. *Adv Med Sci*. 2014;59:190–195.

117. Giannocco G, Oliveira KC, Crajoinas RO, Venturini G, Salles TA, Fonseca-Alaniz MH, Maciel RM, Girardi AC. Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats. *Eur J Pharmacol*. 2013;698:74–86.

118. Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, Roman RJ. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. *J Hypertens*. 2003;21:1125–1135.

119. Skov J, Dejgaard A, Frøkiær J, Holst JJ, Jonassen T, Rittig S, Christiansen JS. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. *J Clin Endocrinol Metab*. 2013;98:E664–E671.

120. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. *J Clin Endocrinol Metab*. 2004;89:3055–3061.

121. Hirata K, Kume S, Araki S, Sakaguchi M, Chin-Kanasaki M, Isshiki K, Sugimoto T, Nishiyama A, Koya D, Haneda M, Kashiwagi A, Uzu T. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. *Biochem Biophys Res Commun*. 2009;380:44–49.

122. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. *Nat Med*. 2013;19:567–575.

123. Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. *Clin Ther*. 2008;30:1448–1460.

124. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. *Lancet*. 2009;373:473–481.

125. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. *Diabetes Obes Metab*. 2013;15:737–749.

126. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. *Diabetes Obes Metab*. 2014;16:38–47.

127. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. *BMJ Open*. 2013;3:e001986.

128. Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, Jiang HH, Threlkeld RJ, Robertson KE, Geiger MJ. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. *Hypertension*. 2014;64:731–737.

129. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. *J Clin Invest*. 2002;110:43–52.

130. Bojanowska E, Stempniak B. Effects of glucagon-like peptide-1(7-36) amide on neurohypophysial and cardiovascular functions under hypo- or normotensive hypovolaemia in the rat. *J Endocrinol*. 2002;172:303–310.

131. Mendis B, Simpson E, MacDonald I, Mansell P. Investigation of the haemodynamic effects of exenatide in healthy male subjects. *Br J Clin Pharmacol*. 2012;74:437–444.

132. Krisai P, Aeschbacher S, Schoen T, Bossard M, van der Stouwe JG, Dörig L, Todd J, Estis J, Risch M, Risch L, Conen D. Glucagon-like peptide-1 and blood pressure in young and healthy adults from the general population. *Hypertension*. 2015;65:306–312.

133. Abd El Motteleb DM, Elshazly SM. Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: role of GLP-1 and GLP-1 receptor. *Eur J Pharmacol*. 2013;720:158–165.

134. Rehfeld JF, Hansen HF, Larsson LI, Stengaard-Pedersen K, Thorn NA. Gastrin and cholecystokinin in pituitary neurons. *Proc Natl Acad Sci USA*. 1984;81:1902–1905.

135. Uvnäs-Wallensten K, Rehfeld JF, Larsson LI, Uvnäs B. Heptadecapeptide gastrin in the vagal nerve. *Proc Natl Acad Sci USA*. 1977;74:5707–5710.

136. Schalling M, Persson H, Pelto-Huikko M, Odum L, Ekman P, Gottlieb C, Hökfelt T, Rehfeld JF. Expression and localization of gastrin messenger RNA and peptide in spermatogenic cells. *J Clin Invest*. 1990;86:660–669.

137. Foucaud M, Archer-Lahlou E, Marco E, Tikhonova IG, Maigret B, Escrieut C, Langer I, Fourmy D. Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin. *Regul Pept*. 2008;145:17–23.

138. de Weerth A, Jonas L, Schade R, Schöneberg T, Wolf G, Pace A, Kirchhoff F, Schulz M, Heinig T, Greten H, von Schrenck T. Gastrin/cholecystokinin type B receptors in the kidney: molecular, pharmacological, functional characterization, and localization. *Eur J Clin Invest*. 1998;28:592–601.

139. How JM, Pumpa TJ, Sartor DM. Renal sympathoinhibitory and regional vasodilator responses to cholecystokinin are altered in obesity-related hypertension. *Exp Physiol*. 2013;98:655–664.

140. Rehfeld JF, Friis-Hansen L, Goetze JP, Hansen TV. The biology of cholecystokinin and gastrin peptides. *Curr Top Med Chem*. 2007;7:1154–1165.

141. Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. *J Clin Invest*. 1985;75:1144–1152.

142. O'Harte FP, Mooney MH, Kelly CM, Flatt PR. Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation. *Diabetes*. 1998;47:1619–1624.

143. Melis M, Krenning EP, Bernard BF, de Visser M, Rolleman E, de Jong M. Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differences. *Nucl Med Biol*. 2007;34:633–641.

144. Survé VV, Håkanson R. Evidence that peroral calcium does not activate the gastrin-ECL-cell axis in the rat. *Regul Pept*. 1998;73:177–1782.

145. Pisegna JR, Tarasova NI, Kopp JA, Asico LD, Jose P, Farnsworth DW, Michejda CJ, Wank SA. Postprandial changes in renal function are mediated by elevated serum gastrin acting at cholecystokinin type B receptors (CCKBR) in the kidney (Abstract). *Gastroenterology*. 1996;110:1106A.

146. Calam J, Gordon D, Peart WS, Taylor SA, Unwin RJ. Renal effects of gastrin C-terminal tetrapeptide (as pentagastrin) and cholecystokinin octapeptide in conscious rabbit and man. *Br J Pharmacol*. 1987;91:307–314.

147. Liu T, Konkalmatt PR, Yang Y, Jose PA. Gastrin decreases Na+, K+-ATPase activity via a PI3-kinase- and PKC-dependent pathway in human renal proximal tubule cells. *Am J Physiol Endocrinol Metab*. 2016;310:E565–E571.

148. Jain RN, Brunkan CS, Chew CS, Samuelson LC. Gene expression profiling of gastrin target genes in parietal cells. *Physiol Genomics*. 2006;24:124–132.

149. Jose PA, Yang Z, Zeng C, Felder RA. The importance of the gastrorenal axis in the control of body sodium homeostasis. *Exp Physiol*. 2016;101:465–470.

150. Sillakivi T, Suumann J, Kirsimägi U, Peetsalu A. Plasma levels of gastric biomarkers in patients after bariatric surgery: biomarkers after bariatric surgery. *Hepatogastroenterology*. 2013;60:2129–2132.

151. Grong E, Arbo IB, Thu OK, Kuhry E, Kulseng B, Mårvik R. The effect of duodenojejunostomy and sleeve gastrectomy on type 2 diabetes mellitus and gastrin secretion in Goto-Kakizaki rats. *Surg Endosc*. 2015;29:723–733.

152. Grong E, Græslie H, Munkvold B, Arbo IB, Kulseng BE, Waldum HL, Mårvik R. Gastrin secretion after bariatric surgery-response to a protein-rich mixed meal following Roux-en-Y gastric bypass and sleeve gastrectomy: a pilot study in normoglycemic women. *Obes Surg*. 2016;26:1448–1456.

153. Jacobsen SH, Olesen SC, Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, Worm D, Almdal T, Naver LS, Hvolris LE, Rehfeld JF, Wulff BS, Clausen TR, Hansen DL, Holst JJ, Madsbad S. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. *Obes Surg*. 2012;22:1084–1096.

154. Meek CL, Lewis HB, Reimann F, Gribble FM, Park AJ. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. *Peptides*. 2016;77:28–37.

155. Nannipieri M, Baldi S, Mari A, Colligiani D, Guarino D, Camastra S, Barsotti E, Berta R, Moriconi D, Bellini R, Anselmino M, Ferrannini E. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. *J Clin Endocrinol Metab*. 2013;98:4391–4399.

156. Inge TH, Courcoulas AP, Jenkins TM, Michalsky MP, Helmrath MA, Brandt ML, Harmon CM, Zeller MH, Chen MK, Xanthakos SA, Horlick M, Buncher CR; Teen-LABS Consortium. Weight loss and health status 3 years after bariatric surgery in adolescents. *N Engl J Med*. 2016;374:113–123.

157. Obeid NR, Malick W, Concors SJ, Fielding GA, Kurian MS, Ren-Fielding CJ. Long-term outcomes after Roux-en-Y gastric bypass: 10- to 13-year data. *Surg Obes Relat Dis*. 2016;12:11–20.

158. Lau RG, Kumar S, Hall CE, Palaia T, Rideout DA, Hall K, Brathwaite CE, Ragolia L. Roux-en-Y gastric bypass attenuates the progression of cardiometabolic complications in obese diabetic rats via alteration in gastrointestinal hormones. *Surg Obes Relat Dis*. 2015;11:1044–1053.

159. de Barros F, Setúbal S, Martinho JM, Monteiro AB. Early endocrine and metabolic changes after bariatric surgery in grade III morbidly obese patients: a randomized clinical trial comparing sleeve gastrectomy and gastric bypass. *Metab Syndr Relat Disord*. 2015;13:264–271.

160. Mallipedhi A, Prior SL, Barry JD, Caplin S, Baxter JN, Stephens JW. Temporal changes in glucose homeostasis and incretin hormone response at 1 and 6 months after laparoscopic sleeve gastrectomy. *Surg Obes Relat Dis*. 2014;10:860–869.

161. Yousseif A, Emmanuel J, Karra E, Millet Q, Elkalaawy M, Jenkinson AD, Hashemi M, Adamo M, Finer N, Fiennes AG, Withers DJ, Batterham RL. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. *Obes Surg*. 2014;24:241–252.

162. Celik F, Ahdi M, Meesters EW, van de Laar A, Brandjes DP, Gerdes VE. The longer-term effects of Roux-en-Y gastric bypass surgery on sodium excretion. *Obes Surg*. 2013;23:358–364.

163. Agrawal V, Liu XJ, Campfield T, Romanelli J, Enrique Silva J, Braden GL. Calcium oxalate supersaturation increases early after Roux-en-Y gastric bypass. *Surg Obes Relat Dis*. 2014;10:88–94.

164. Bueter M, Ashrafian H, Frankel AH, Tam FW, Unwin RJ, le Roux CW. Sodium and water handling after gastric bypass surgery in a rat model. *Surg Obes Relat Dis*. 2011;7:68–73.

165. Friedman AN, Quinney SK, Inman M, Mattar SG, Shihabi Z, Moe S. Influence of dietary protein on glomerular filtration before and after bariatric surgery: a cohort study. *Am J Kidney Dis*. 2014;63:598–603.

166. Premaratne E, Verma S, Ekinci EI, Theverkalam G, Jerums G, MacIsaac RJ. The impact of hyperfiltration on the diabetic kidney. *Diabetes Metab*. 2015;41:5–17.

167. Orlov SN, Koltsova SV, Kapilevich LV, Gusakova SV, Dulin NO. NKCC1 and NKCC2: the pathogenetic role of cation-chloride cotransporters in hypertension. *Genes Dis*. 2015;2:186–196.

168. Gao F, Sui D, Garavito RM, Worden RM, Wang DH. Salt intake augments hypotensive effects of transient receptor potential vanilloid 4: functional significance and implication. *Hypertension*. 2009;53:228–235.

169. Drexler H, Hänze J, Finckh M, Lu W, Just H, Lang RE. Atrial natriuretic peptide in a rat model of cardiac failure. Atrial and ventricular mRNA, atrial content, plasma levels, and effect of volume loading. *Circulation*. 1989;79:620–633.

170. Harris RC, Zhang MZ. Dopamine, the kidney, and hypertension. *Curr Hypertens Rep*. 2012;14:138–143.

171. Padia SH, Kemp BA, Howell NL, Keller SR, Gildea JJ, Carey RM. Mechanisms of dopamine D(1) and angiotensin type 2 receptor interaction in natriuresis. *Hypertension*. 2012;59:437–445.

172. Banday AA, Lokhandwala MF. Dopamine receptors and hypertension. *Curr Hypertens Rep*. 2008;10:268–275.

173. Zeng C, Eisner GM, Felder RA, Jose PA. Dopamine receptor and hypertension. *Curr Med Chem Cardiovasc Hematol Agents*. 2005;3:69–77.

174. Choi MR, Kouyoumdzian NM, RukavinaMikusic NL, Kravetz MC, Rosón MI, Rodríguez Fermepin M, Fernández BE. Renal dopaminergic system: pathophysiological implications and clinical perspectives. *World J Nephrol*. 2015;4:196–212.

175. Banday AA, Lokhandwala MF. Oxidative stress reduces renal dopamine D$_1$ receptor-Gq/11alpha G protein-phospholipase C signaling involving G protein-coupled receptor kinase 2. *Am J Physiol Renal Physiol*. 2007;293:F306–F315.

176. Gildea JJ, Shah IT, Van Sciver RE, Israel JA, Enzensperger C, McGrath HE, Jose PA, Felder RA. The cooperative roles of the dopamine receptors, D$_1$R and D$_5$R, on the regulation of renal sodium transport. *Kidney Int*. 2014;86:118–126.

177. Lee SP, So CH, Rashid AJ, Varghese G, Cheng R, Lança AJ, O'Dowd BF, George SR. Dopamine D$_1$ and D$_2$ receptor Co-activation generates a novel phospholipase C-mediated calcium signal. *J Biol Chem*. 2004;279:35671–35678.

178. Jiang X, Chen W, Liu X, Wang Z, Liu Y, Felder RA, Gildea JJ, Jose PA, Qin C, Yang Z. The synergistic roles of cholecystokinin B and dopamine $D_5$ receptors on the regulation of renal sodium excretion. *PLoS One*. 2016;11:e0146641.

179. Horita S, Nakamura M, Suzuki M, Satoh N, Suzuki A, Seki G. Selective insulin resistance in the kidney. *Biomed Res Int*. 2016;2016:5825170.

180. Zhang Y, Ren H, Lu X, He D, Han Y, Wang H, Zeng C, Shi W. Inhibition of $D_4$ dopamine receptors on insulin receptor expression and effect in renal proximal tubule cells. *J Am Heart Assoc*. 2016;5:e002448. DOI: 10.1161/JAHA.115.002448.

181. Nakamura M, Yamazaki O, Shirai A, Horita S, Satoh N, Suzuki M, Hamasaki Y, Noiri E, Kume H, Enomoto Y, Homma Y, Seki G. Preserved $Na/HCO_3$ cotransporter sensitivity to insulin may promote hypertension in metabolic syndrome. *Kidney Int*. 2015;87:535–542.

182. Baudrand R, Campino C, Carvajal CA, Olivieri O, Guidi G, Faccini G, Vöhringer PA, Cerda J, Owen G, Kalergis AM, Fardella CE. High sodium intake is associated with increased glucocorticoid production, insulin resistance and metabolic syndrome. *Clin Endocrinol (Oxf)*. 2014;80:677–684.

183. Carranza A, Musolino PL, Villar M, Nowicki S. Signaling cascade of insulin-induced stimulation of L-dopa uptake in renal proximal tubule cells. *Am J Physiol Cell Physiol*. 2008;295:C1602–C1609.

184. Ahmad Banday A, Lokhandwala MF. Defective renal dopamine $D_1$ receptor function contributes to hyperinsulinemia-mediated hypertension. *Clin Exp Hypertens*. 2006;28:695–705.

185. Banday AA, Fazili FR, Lokhandwala MF. Insulin causes renal dopamine $D_1$ receptor desensitization via GRK2-mediated receptor phosphorylation involving phosphatidylinositol 3-kinase and protein kinase C. *Am J Physiol Renal Physiol*. 2007;293:F877–F884.

186. Trivedi M, Lokhandwala MF. Rosiglitazone restores renal $D_1A$ receptor-Gs protein coupling by reducing receptor hyperphosphorylation in obese rats. *Am J Physiol Renal Physiol*. 2005;289:F298–F304.

187. Yang J, Cui Z, He D, Ren H, Han Y, Yu C, Fu C, Wang Z, Yang C, Wang X, Zhou L, Asico LD, Villar VA, Hopfer U, Mi M, Zeng C, Jose PA. Insulin increases $D_5$ dopamine receptor expression and function in renal proximal tubule cells from Wistar-Kyoto rats. *Am J Hypertens*. 2009;22:770–776.

188. Li F, Yang J, Jones JE, Villar VA, Yu P, Armando I, Felder RA, Jose PA. Sorting nexin 5 and dopamine D1 receptor regulate the expression of the insulin receptor in human renal proximal tubule cells. *Endocrinology*. 2015;156:2211–2221.

189. Rubí B, Ljubicic S, Pournourmohammadi S, Carobbio S, Armanet M, Bartley C, Maechler P. Dopamine $D_2$-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. *J Biol Chem*. 2005;280:36824–36832.

190. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, Pijl H, Guigas B. The dopamine receptor $D_2$ agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. *Biochem Pharmacol*. 2010;79:1827–1836.

191. García-Tornadú I, Ornstein AM, Chamson-Reig A, Wheeler MB, Hill DJ, Arany E, Rubinstein M, Becu-Villalobos D. Disruption of the dopamine D2 receptor impairs insulin secretion and causes glucose intolerance. *Endocrinology*. 2010;151:1441–1450.

192. Carey RM. The intrarenal renin-angiotensin system in hypertension. *Adv Chronic Kidney Dis*. 2015;22:204–210.

193. Santos PC, Krieger JE, Pereira AC. Renin-angiotensin system, hypertension, and chronic kidney disease: pharmacogenetic implications. *J Pharmacol Sci*. 2012;120:77–88.

194. Siragy HM. Angiotensin II compartmentalization within the kidney: effects of salt diet and blood pressure alterations. *Curr Opin Nephrol Hypertens*. 2006;15:50–53.

195. Kim YH, Hwang JH, Kim KS, Noh JR, Gang GT, Kim SW, Jang SP, Lee SJ, Her SH, Jeong KH, Kwak TH, Park WJ, Balyasnikova IV, Shong M, Lee CH. NQO1 activation regulates angiotensin-converting enzyme shedding in spontaneously hypertensive rats. *Cardiovasc Res*. 2013;99:743–750.

196. Li XC, Zhuo JL. Recent updates on the proximal tubule renin-angiotensin system in angiotensin II-dependent hypertension. *Curr Hypertens Rep*. 2016;18:63.

197. Liu Q, Adams L, Broyde A, Fernandez R, Baron AD, Parkes DG. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. *Cardiovasc Diabetol*. 2010;9:32.

198. Alter ML, Ott IM, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K, Raila J, Henze A, Klein T, Hocher B. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. *Kidney Blood Press Res*. 2012;36:119–130.

199. Gil-Lozano M, Pérez-Tilve D, Alvarez-Crespo M, Martís A, Fernandez AM, Catalina PA, Gonzalez-Matias LC, Mallo F. GLP-1(7-36)-amide and exendin-4 stimulate the HPA axis in rodents and humans. *Endocrinology*. 2010;151:2629–2640.

200. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, Zadeh M, Gong M, Qi Y, Zubcevic J, Sahay B, Pepine CJ, Raizada MK, Mohamadzadeh M. Gut dysbiosis is linked to hypertension. *Hypertension*. 2015;65:1331–1340.

201. Mell B, Jala VR, Mathew AV, Byun J, Waghulde H, Zhang Y, Haribabu B, Vijay-Kumar M, Pennathur S, Joe B. Evidence for a link between gut microbiota and hypertension in the Dahl rat. *Physiol Genomics*. 2015;47:187–197.

202. Adnan S, Nelson JW, Ajami NJ, Venna VR, Petrosino JF, Bryan RM Jr, Durgan DJ. Alterations in the gut microbiota can elicit hypertension in rats. *Physiol Genomics*. 2017;49:96–104.

203. Miyamoto J, Kasubuchi M, Nakajima A, Irie J, Itoh H, Kimura I. The role of short-chain fatty acid on blood pressure regulation. *Curr Opin Nephrol Hypertens*. 2016;25:379–383.

204. Afsar B, Vaziri ND, Aslan G, Tarim K, Kanbay M. Gut hormones and gut microbiota: implications for kidney function and hypertension. *J Am Soc Hypertens*. 2016;10:954–961.

205. Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J, Brunet I, Wan LX, Rey F, Wang T, Firestein SJ, Yanagisawa M, Gordon JI, Eichmann A, Peti-Peterdi J, Caplan MJ. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. *Proc Natl Acad Sci USA*. 2013;110:4410–4415.

206. Ridaura V, Belkaid Y. Gut microbiota: the link to your second brain. *Cell*. 2015;161:193–194.

207. Asano Y, Hiramoto T, Nishino R, Aiba Y, Kimura T, Yoshihara K, Koga Y, Sudo N. Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice. *Am J Physiol Gastrointest Liver Physiol*. 2012;303:G1288–G1295.

208. Crumeyrolle-Arias M, Jaglin M, Bruneau A, Vancassel S, Cardona A, Daugé V, Naudon L, Rabot S. Absence of the gut microbiota enhances anxiety-like behavior and neuroendocrine response to acute stress in rats. *Psychoneuroendocrinology*. 2014;42:207–217.

209. Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, Deng Y, Blennerhassett P, Macri J, McCoy KD, Verdu EF, Collins SM. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. *Gastroenterology*. 2011;141:599–609.

210. Keenan MJ, Martin RJ, Raggio AM, McCutcheon KL, Brown IL, Birkett A, Newman SS, Skaf J, Hegsted M, Tulley RT, Blair E, Zhou J. High-amylose resistant starch increases hormones and improves structure and function of the gastrointestinal tract: a microarray study. *J Nutrigenet Nutrigenomics*. 2012;5:26–44.

211. Marques FZ, Nelson EM, Chu PY, Horlock D, Fiedler A, Ziemann M, Tan JK, Kuruppu S, Rajapakse NW, El-Osta A, Mackay CR, Kaye DM. High fibre diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in DOCA-salt hypertensive mice. *Circulation*. 2016. Available at: http://circ.ahajournals.org/content/early/2016/12/07/CIRCULATIONAHA.116.024545. Accessed Feburary 28, 2017.

**Key Words:** blood pressure • gastrointestinal tract • hypertension • kidney • salt sensing

# Journal of the American Heart Association

OPEN ACCESS

American Heart Association | American Stroke Association

**Gastrointestinal−Renal Axis: Role in the Regulation of Blood Pressure**
Jian Yang, Pedro A. Jose and Chunyu Zeng

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://jaha.ahajournals.org/content/6/3/e005536